The Frazier Life Sciences team invests in and builds companies developing and commercializing novel therapeutics. The team is currently investing out of a $419 million Life Sciences-focused fund (2018 vintage).

Company formation has been a core strategy since 2005. The Frazier team leverages its extensive relationships with pharmaceutical companies and academic institutions to identify and license assets into focused new companies with exceptional management teams.

The Frazier team is active in investing across all rounds of private companies, focusing on opportunities with meaningful clinical read-outs for diseases with unmet medical need.

The Frazier team invests in mezzanine financings and public markets, and takes a long-term view of these investments.

Selected Drug Approvals from our Portfolio

Silvergate Pharmaceuticals
Nabriva Therapeutics
Ignyta
Acerta Pharma
Amicus Therapeutics
Portola Pharmaceuticals
Portola Pharmaceuticals
Rempex Pharmaceuticals
View More